BOLD-302 NSCLC (#442)
Laufzeit: 01.01.2013 - 31.12.2017
imported
Kurzfassung
A randomized, open-label, multicenter, phase III study to compare the efficacy and safety of Eribulin with treatment of physician’s choice in subjects with advanced non-small cell lung cancer
